CLVS - Clovis Oncology, Inc.
| Previous Close | 24.00 |
| Open | 23.71 |
| Bid | 22.73 x 1000 |
| Ask | 23.50 x 1400 |
| Day's Range | 22.55 - 23.85 |
| 52 Week Range | 11.50 - 65.24 |
| Volume | 1,628,488 |
| Avg. Volume | 3,032,787 |
| Market Cap | 1.194B |
| Beta (3Y Monthly) | 2.13 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.24 |
| Earnings Date | Feb 26, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.10 |
- Zacks•5 days ago
Immunomedics Gets CRL From FDA for Breast Cancer Candidate
Immunomedics (IMMU) receives a CRL from the FDA pertaining to the BLA for its lead breast cancer candidate, sacituzumab govitecan.
- Investor's Business Daily•6 days ago
Lilly's 10-Day Sprint For Loxo Could Put Other Names On The Table
Pharma giant Eli Lilly put together its winning bid for Loxo Oncology in just 10 days ahead of the J.P. Morgan Healthcare Conference, according to documents filed Thursday with the SEC.
- Markit•8 days ago
See what the IHS Markit Score report has to say about Clovis Oncology Inc.
# Clovis Oncology Inc ### NASDAQ/NGS:CLVS View full report here! ## Summary * Bearish sentiment is high but may be declining ## Bearish sentiment Short interest | Negative Short interest is high for CLVS with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting CLVS. However, sentiment has improved and traders reduced their bearish short positions on December 20. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $2.97 billion over the last one-month into ETFs that hold CLVS are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Motley Fool•11 days ago
3 Biotech Stocks That Soared This Week: Are They Buys?
These biotech stocks jumped 31% or more over the last few days. Can their momentum continue?
- Zacks•12 days ago
Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
- ACCESSWIRE•13 days ago
Kill the Cancer Stem Cell, Kill the Cancer: How One Biotech is Hitting Cancer at the Cause
TORONTO, ON / ACCESSWIRE / January 10, 2019 / The Wealthy Biotech Trader (or ''WBT''), an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharma, medical device stocks making news and subsequent market moves, would like to update investors on several breakthroughs in cancer therapies hitting the market. Stock investors have soured on biotech companies over the past several months, as demonstrated by the SPDR S&P Biotech ETF (XBI), off 30% since June, and the NYSE Biotechnology Index (NYSE:NBI), which has dropped from 3500 in mid-2018 to just under 3000 at year-end, and a host of their component companies and others in addition. One of those is Propanc Biopharma, Inc. (OTCQB:PPCB), an Australian biotech company with strong management and technology that has the potential to help millions of cancer patients worldwide.
- Markit•14 days ago
See what the IHS Markit Score report has to say about Clovis Oncology Inc.
# Clovis Oncology Inc ### NASDAQ/NGS:CLVS View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high but may be declining ## Bearish sentiment Short interest | Negative Short interest is high for CLVS with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting CLVS. However, sentiment has improved and traders reduced their bearish short positions on December 20. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding CLVS is favorable, with net inflows of $5.63 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Schaeffer's Investment Research•15 days ago
History Says Pump the Brakes on a Clovis Oncology Stock Rally
CLVS stock rallied more than 18% yesterday
- Motley Fool•16 days ago
Here's Why Clovis Oncology Rose as Much as 21.9% Today
The down-on-its-luck pharma company turned in a solid year of growth. Will it be enough to remain competitive -- or find a suitor?
- Business Wire•16 days ago
Clovis Oncology Announces Product Revenues for the Fourth Quarter and Full Year 2018
BOULDER, Colo.-- -- Estimated $30.3-$30.8M in Rubraca ® sales for Q4 2018 and $95.3-$95.8M for FY2018 Q4/FY2018 Operating Results planned for February 26, 2019 Clovis Oncology , Inc. today announced its preliminary, unaudited revenues for the fourth quarter and full year ended December 31, 2018. The financial information presented in this news release may be adjusted as a result of completion of customary ...
- Business Wire•21 days ago
Clovis Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference
Clovis Oncology, Inc. today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019 at 4:30 p.m.
- Zacks•27 days ago
Immunomedics Enters Into Supply Deal for Breast Cancer Drug
Immunomedics (IMMU) entered into a long-term master supply agreement for lead candidate, sacituzumab govitecan.
- GlobeNewswire•28 days ago
Detailed Research: Economic Perspectives on Canopy Growth, ArQule, MoneyGram International, Teradata, Clovis Oncology, and Axovant Sciences — What Drives Growth in Today's Competitive Landscape
NEW YORK, Dec. 26, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Markit•last monthSee what the IHS Markit Score report has to say about Clovis Oncology Inc.
Short interest is high for CLVS with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting CLVS. Over the last month, ETFs holding CLVS are favorable, with net inflows of $3.11 billion.
- Zacks•last month
AstraZeneca's (AZN) Lynparza Gets FDA Nod in 1st Line Setting
AstraZeneca's (AZN) Lynparza receives FDA approval for first-line maintenance treatment of advanced ovarian cancer.
Markit•last monthSee what the IHS Markit Score report has to say about Clovis Oncology Inc.
Short interest is high for CLVS with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting CLVS. ETFs that hold CLVS had net inflows of $1.53 billion over the last one-month.
- Insider Monkey•last month
Argentiere Capital’s Returns, AUM and Holdings
Deepak Gulati‘s Argentiere Capital is a Zug, Switzerland-based hedge fund launched back in June 2013, with an additional office in Chicago. The fund is focused on offering its services to pooled investment vehicles and manages separate client-focused equity portfolios. It’s run by a team of former members of JP Morgan’s Global Equities Proprietary Trading Group […]
- Motley Fool•last month
3 Biotechs Gilead Sciences Could Buy in March
With a new CEO from Roche on the way, these companies' odds of being acquired just rose a notch.
Zacks•last monthDo Options Traders Know Something About Clovis (CLVS) Stock We Don't?
Investors need to pay close attention to Clovis (SFIX) stock based on the movements in the options market lately.
Markit•last monthSee what the IHS Markit Score report has to say about Clovis Oncology Inc.
Clovis Oncology Inc NASDAQ/NGS:CLVS
- Business Wire•last month
CHMP Grants Positive Opinion for New Indication of Clovis Oncology’s Rubraca®▼ (rucaparib) Tablets as Maintenance Treatment for Women with Relapsed Ovarian Cancer
BOULDER, Colo.-- -- European Commission marketing authorization is anticipated Q1 2019 Upon receipt of marketing authorization by the EC, Rubraca will offer a new monotherapy option for the maintenance treatment of adults with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response to platinum-based chemotherapy Clovis Oncology, Inc. ...
- Markit•last month
See what the IHS Markit Score report has to say about Clovis Oncology Inc.
# Clovis Oncology Inc ### NASDAQ/NGS:CLVS Score: Negative (5) 58 days at current score. Downgraded from Neutral on October 17th 2018 View full report here! ## Summary * This company ranked negatively compared to the Healthcare sector despite only 1 negative IHS Markit Category * Bearish sentiment is high and has been increasing * Economic output in this company's sector is expanding ## Bearish sentiment Short interest | Negative Short interest is high for CLVS with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting CLVS. Sentiment has worsened and traders added to their bearish short positions on December 11. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. ETFs that hold CLVS had net inflows of $1.43 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. ## Economic sentiment PMI by IHS Markit | Positive According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Market Realist•last monthWhat’s the Market Opportunity for Zejula?
How Is Tesaro Positioned in December? As per GlaxoSmithKline’s (GSK) analyst call transcript, Tesaro’s (TSRO) Zejula is competing with AstraZeneca’s (AZN) Lynparza and Clovis Oncology’s (CLVS) Rubraca as maintenance therapy in the second-line platinum-sensitive ovarian cancer indication. GlaxoSmithKline (GSK) has estimated the annual incidence of these patients in the US market to be around 5,000.
Market Realist•last monthWhy Portola Pharmaceuticals’ Stock Price Is Plummeting Today
Today, Portola Pharmaceuticals is trading at $19.32, which is a ~7.52% decline from yesterday’s close of $20.89 on December 10. That day, the stock price closed at $20.89, which is a ~63% fall from its 52-week high of $56.70 on December 21, 2017. The stock price fell from $48.68 at the close of the market on December 29, 2017, to $20.89 on December 10, 2018, reflecting a ~57% YTD (year-to-date) fall. Portola Pharmaceuticals hit a 52-week low of $18.18 on November 7.
